Reconstitution chart: 10 mg vial
| BAC water added | Concentration | Draw for 1 mg dose | Draw for 1.75 mg dose |
|---|---|---|---|
| 1 mL | 10,000 mcg/mL | 10 units | 17.5 units |
| 2 mL | 5,000 mcg/mL | 20 units | 35 units |
Draws are U-100 insulin syringe units (100 units = 1 mL). Formula: dose in mcg ÷ (vial mcg ÷ water mL) × 100. The calculator above handles any other combination.
About PT-141
PT-141, generic name bremelanotide, is a melanocortin receptor agonist that took an unusual road: it was developed out of Melanotan II research after researchers noticed effects on sexual desire, and in 2019 it earned FDA approval as Vyleesi, an autoinjector for premenopausal women with hypoactive sexual desire disorder. So unlike most compounds on this site, an approved, labeled reference product exists.
The approved label doses Vyleesi at 1.75 mg subcutaneously as needed, at least 45 minutes before anticipated activity, with hard limits of one dose per 24 hours and eight doses per month. Nausea is the most commonly reported side effect on the label, affecting a large share of users, and the label warns about temporary blood pressure increases. Gray-market PT-141 ships as 10 mg powder vials, and people of all sexes use it off-label, which the label never studied.
The math: a 10 mg vial with 2 mL of BAC water yields a concentration of 5,000 mcg per mL, putting the label-equivalent 1.75 mg dose at a 35 unit draw. The half-life runs around 2.7 hours. If your draw lands above your syringe size, the fix is less water, a bigger syringe, or accepting two sticks; never guess at a partial draw.
Quick facts
- Status: FDA approved as Vyleesi (1.75 mg autoinjector) for one specific indication; vial powder is gray-market
- Label limits: one dose per 24 hours, max eight per month; nausea is the most common reported effect
- Half-life: roughly 2.7 hours
- Standard gray vial: 10 mg powder